Market Overview

Bonti Announces Hot Topics Presentation of Phase 2a Interim Clinical Data at The Aesthetic Meeting 2017


Bonti, a privately-held, clinical-stage biotechnology company, today
announced the debut presentation of interim clinical data from Phase 2
study EB-001-GL201 of EB-001 in subjects with glabellar (frown) lines.
Dr. Steve Yoelin, a co-principal investigator of the study, led off the
highly attended Premier Global Hot Topics session at The Aesthetic
Meeting 2017, organized by the American Society of Aesthetic Plastic
Surgery (ASAPS), on April 28th in San Diego, CA. EB-001 is a
novel Type E botulinum neurotoxin with a unique clinical profile,
characterized by fast onset of effect. EB-001 will target aesthetic and
therapeutic indications with multi-billion dollar addressable market

Dr. Yoelin, a world-renowned neurotoxin and facial aesthetics expert, is
a co-principal investigator of the EB-001 Phase 2a clinical study (Study
EB-001-GL-201). He highlighted the study design and previewed interim
safety and efficacy data in his presentation. EB-001 is currently being
evaluated in subjects with moderate to severe glabellar (frown) lines in
a placebo-controlled, ascending dose cohort study which includes a
single treatment cycle and follow-up for 28 days.

A total of 24 subjects in 4 cohorts have been treated to date (20
received active drug, 4 received placebo). Review of blinded data
suggests EB-001 is safe and well-tolerated at the doses administered so
far. In blinded cohorts 3 and 4, several subjects showed a two point
decrease in severity of glabellar lines, using the facial wrinkle scale,
according to investigator assessment of severity. The onset of response
was within 24 hours of treatment. Dose escalation will continue in order
to determine the maximum efficacious dose and its duration of effect.
Final study results will allow dose selection for future studies, and
will be submitted for publication.

"The Bonti team, including our clinical investigators, was delighted
when we began seeing positive data from our ongoing study and we are
thrilled to have shared interim findings with key members of the medical
community for the first time," remarked Fauad Hasan, co-founder and CEO
of Bonti. "It was a privilege to have Dr. Yoelin speak on our behalf and
we are thankful to the ASAPS for choosing EB-001 for the Hot Topics
forum. As we previously announced, the results from this study will not
only be important in addressing unmet needs in facial aesthetics in the
future, they will also enable Bonti to advance its therapeutic
development program to study EB-001 as a non-opioid solution for the
treatment of musculoskeletal pain."

"This is a significant step forward for Bonti and I foresee EB-001 being
a valuable addition to our aesthetic toolbox," remarked Dr. Jean
Carruthers, a pioneer in the cosmetic use of Type A botulinum
neurotoxin and currently a Bonti Medical Advisor. "I'm excited to see
how rapidly this unique neurotoxin has progressed from the lab to the
clinic. We've been waiting for this new option for a long time."

About Dr. Steve Yoelin

Dr. Yoelin is a board-certified physician who currently practices in
Newport Beach, CA and has been a thought leader in the clinical and
research fields. For the past decade he has developed an unprecedented
expertise in facial aesthetics including the use of neurotoxins, dermal
fillers and collagen stimulators. Dr. Yoelin is focused on innovation
and has served as lead investigator in several pilot studies for novel
agents, including one that led to a first-in-class FDA approved
aesthetic product. Dr. Yoelin has lectured extensively on the use of
facial injectables at numerous educational events in the U.S. and at
international conferences.

About Dr. Jean Carruthers

Dr. Carruthers is Clinical Professor of Ophthalmology at the University
of British Columbia. With her dermatologist husband Dr. Alastair
Carruthers, she pioneered the cosmetic use of Type A botulinum
neurotoxins and their combined use with three dimensional fillers,
energy based devices and cosmetic surgery. She has published 288 peer
reviewed scientific papers, 69 textbook chapters and 9 textbooks on this
area and continues a very active research department. She is Fellow of
the Royal College of Surgeons in Canada, the Royal College of
Ophthalmologists in the UK and Fellow of the American Society of
Ophthalmic Plastic and Reconstructive Surgery. She has given more than
300 presentations worldwide on topics in cosmetic medicine and surgery.
She has received several awards including in 2017 the highest honour of
the American Society for Dermatologic Surgery, the Samuel J Stegman
Award. Dr. Carruthers has been profiled in numerous publications
including Best Doctors in Canada, the New York Times, Allure magazine,
Time, Newsweek and Vogue. She has also been featured on the television
program 20/20.

About EB-001

Bonti's lead product candidate, EB-001, is an investigational botulinum
neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar
to the marketed BoNT/A products though it has a differentiated clinical
profile. EB-001 has a fast onset of action (about 24 hours) and short
duration of effect (about 4 weeks). Currently marketed BoNT/A products
have an onset of action around 3-7 days and a duration of effect around
3-4 months. The unique target clinical profile of EB-001 is well suited
for a vast range of aesthetic and therapeutic uses, including for the
treatment of post-surgical and non-surgical musculoskeletal pain, with
currently unmet needs. Study EB-001-GL-201, focusing on treatment of
glabellar (frown) lines, is currently ongoing (

About Bonti

Bonti, based in Newport Beach, California, is a rapidly emerging
biotechnology company founded by world class neurotoxin experts with
proven success at Allergan, one of the Fortune 500 fastest growing
pharma companies. This team, with unsurpassed neurotoxin, aesthetic and
pain expertise, is uniquely qualified to develop unprecedented treatment
paradigms driven by a novel neurotoxin platform to become an innovative
leader in both aesthetic and therapeutic markets. By turning the science
of neurotoxins into beneficial patient and healthcare provider
solutions, Bonti will improve lives by successfully addressing key unmet
needs in markets with multi-billion dollar addressable opportunities.

For more information, please visit

View Comments and Join the Discussion!